BRPI0817525A2 - COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER. - Google Patents

COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER.

Info

Publication number: BRPI0817525A2
Authority: BR; Brazil
Prior art keywords: disorder; disease; prevention; compound; treatment
Prior art date: 2007-09-26

Application number

BRPI0817525-0A2A

Other languages

Portuguese (pt)

Inventor

George W Muller

Hon-Wah Man

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-26

Filing date

2008-09-25

Publication date

2014-11-18

2008-09-25 Application filed by Celgene Corp filed Critical Celgene Corp

2014-11-18 Publication of BRPI0817525A2 publication Critical patent/BRPI0817525A2/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0817525-0A2A 2007-09-26 2008-09-25 COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER. BRPI0817525A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99567607P	2007-09-26	2007-09-26
PCT/US2008/011124 WO2009042177A1 (en)	2007-09-26	2008-09-25	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Publications (1)

Publication Number	Publication Date
BRPI0817525A2 true BRPI0817525A2 (en)	2014-11-18

Family

ID=40225265

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817525-0A2A BRPI0817525A2 (en)	2007-09-26	2008-09-25	COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER.

Country Status (22)

Country	Link
US (5)	US8492395B2 (en)
EP (1)	EP2200999B1 (en)
JP (1)	JP5637852B2 (en)
KR (1)	KR101593242B1 (en)
CN (2)	CN104211684A (en)
AU (1)	AU2008305581C1 (en)
BR (1)	BRPI0817525A2 (en)
CA (1)	CA2704710C (en)
CO (1)	CO6270228A2 (en)
CR (1)	CR11355A (en)
ES (1)	ES2523925T3 (en)
HK (1)	HK1139934A1 (en)
IL (2)	IL204763A (en)
MX (1)	MX347987B (en)
MY (1)	MY157495A (en)
NI (1)	NI201000041A (en)
NZ (1)	NZ584425A (en)
RU (1)	RU2476432C2 (en)
SG (2)	SG176442A1 (en)
UA (1)	UA102078C2 (en)
WO (1)	WO2009042177A1 (en)
ZA (1)	ZA201002303B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200901950B (en)	2006-09-26	2010-06-30	Celgene Corp	5-substituted quinazolinone derivatives as antitumor agents
US8354417B2 (en) *	2007-09-26	2013-01-15	Celgene Corporation	Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
HUE026296T2 (en) *	2009-08-31	2016-06-28	Merck Sharp & Dohme	Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2490692B1 (en)	2009-10-21	2016-11-16	Merck Sharp & Dohme Corp.	Quinolinone-pyrazolone m1 receptor positive allosteric modulators
AU2012229300B2 (en) *	2011-03-11	2017-04-20	Celgene Corporation	Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
DK2683708T3 (en)	2011-03-11	2018-01-29	Celgene Corp	SOLID FORMS OF 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL) -PIPERIDIN-2,6-DION AND PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF
WO2012135299A1 (en)	2011-03-28	2012-10-04	Deuteria Pharmaceuticals Inc	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2014205043B2 (en)	2013-01-14	2018-10-04	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014152833A1 (en) *	2013-03-14	2014-09-25	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014172436A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP2016521280A (en) *	2013-05-03	2016-07-21	セルジーンコーポレイション	How to treat cancer with combination therapy
HUE061382T2 (en)	2014-08-22	2023-06-28	Celgene Corp	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
JP6727237B2 (en)	2015-07-02	2020-07-22	セルジーンコーポレイション	Combination therapy for the treatment of hematological cancers and solid tumors
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
KR102331013B1 (en)	2016-01-14	2021-11-26	강푸 바이오파마슈티칼즈 리미티드	Quinazolinone derivatives, preparation method thereof, pharmaceutical composition and application
EP3454862B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
EP4491236A3 (en)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
EP3455219A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
EP3455218A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	CARBON-BONDED GLUTARIMIDE-TYPE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2018208123A1 (en) *	2017-05-12	2018-11-15	한국화학연구원	Novel piperidine-2,6-dione derivative and use thereof
KR102014478B1 (en) *	2017-05-12	2019-08-26	한국화학연구원	Novel piperidine-2,6-dione derivatives and use thereof
EP3641762A4 (en)	2017-06-20	2021-03-10	C4 Therapeutics, Inc.	N/o-linked degrons and degronimers for protein degradation
CN111315735B (en)	2017-09-04	2024-03-08	C4医药公司	Dihydrobenzimidazolone
WO2019043214A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	Glutarimide
EP3679028A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Dihydroquinolinones
JP2021501198A (en) *	2017-10-27	2021-01-14	トランスフュージョンヘルス，リミティドライアビリティカンパニー	Compositions and Methods for Proliferating Hematopoietic Stem Cells Using Fluorene Derivatives
CN111372585A (en)	2017-11-16	2020-07-03	C4医药公司	Degradants and degreddeterminants for target protein degradation
CN111902141A (en)	2018-03-26	2020-11-06	C4医药公司	Glucocerebroside binders for IKAROS degradation
CN112312904B (en)	2018-04-16	2025-01-07	C4医药公司	Spirocyclic compounds
EP3578561A1 (en)	2018-06-04	2019-12-11	F. Hoffmann-La Roche AG	Spiro compounds
WO2020210630A1 (en)	2019-04-12	2020-10-15	C4 Therapeutics, Inc.	Tricyclic degraders of ikaros and aiolos
WO2021168314A1 (en)	2020-02-21	2021-08-26	Plexium, Inc.	Quinazolinone compounds and related compounds
AU2021323851B2 (en) *	2020-08-14	2024-08-29	Shanghaitech University	Immunoregulatory compounds and anti-tumor application thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en)	1989-03-22	1991-07-25	Bioresearch Spa	USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (en)	1990-01-23	1999-01-15	.	Cyclodextrin derivatives with increased water solubility and uses thereof
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
WO1995003807A1 (en)	1993-07-27	1995-02-09	The University Of Sydney	Treatment of age-related macular degeneration
IT1270594B (en)	1994-07-07	1997-05-07	Recordati Chem Pharm	CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
IT1274549B (en)	1995-05-23	1997-07-17	Indena Spa	USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
US5800819A (en)	1996-01-25	1998-09-01	National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology	Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
DK0901487T3 (en) *	1996-05-15	2003-08-25	Pfizer	2,3,6-trisubstituted 4 (3H) -quinazolinones
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
ATE530542T1 (en)	1996-07-24	2011-11-15	Celgene Corp	AMINO SUBSTITUTED 2-(2,6-DIOXOPIPERIDINE-3-YL)-PHTHALIMIDE TO REDUCE TNF-ALPHA LEVELS
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
TR200101504T2 (en) *	1998-03-16	2002-06-21	Celgene Corporation	2- (2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and use as inhibitors of inflammatory cytokines.
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en)	1998-09-03	1999-12-14	Protein Technologies International, Inc.	Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
CN1511420A (en)	2001-11-09	2004-07-07	松下电器产业株式会社	Motion picture encoding method and device
US7381730B2 (en)	2002-03-15	2008-06-03	Bristol-Myers Squibb Company	3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US7323479B2 (en)	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7211580B2 (en) *	2002-07-23	2007-05-01	Cytokinetics, Incorporated	Compounds, compositions, and methods
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en)	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en)	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
GB0324790D0 (en) *	2003-10-24	2003-11-26	Astrazeneca Ab	Amide derivatives
US20050100529A1 (en)	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20110116225A (en)	2003-12-02	2011-10-25	셀진 코포레이션	Methods and compositions for the treatment and management of hemochromatosis and anemia
US20050143344A1 (en)	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
WO2005091991A2 (en)	2004-03-22	2005-10-06	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US8084459B2 (en) *	2004-04-02	2011-12-27	Prana Biotechnology Ltd	Substituted quinazolinones for treating neurological conditions
ZA200609226B (en)	2004-04-23	2008-06-25	Celgene Corp	Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of pulmonary hypertension
WO2005123696A1 (en) *	2004-06-15	2005-12-29	Astrazeneca Ab	Substituted quinazolones as anti-cancer agents
JP2008519844A (en)	2004-11-12	2008-06-12	セルジーン・コーポレーション	Methods and compositions using immunomodulatory compounds for the treatment and management of parasitic diseases
ZA200704890B (en)	2004-11-23	2008-09-25	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US8394832B2 (en)	2004-12-01	2013-03-12	Celgene Corporation	Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
RU2008112221A (en)	2005-08-31	2009-10-10	Селджин Корпорейшн (Us)	COMPOUNDS OF A NUMBER OF ISOINDOLIMIDES, THEIR COMPOSITIONS AND METHODS OF APPLICATION
ES2485316T3 (en)	2005-09-01	2014-08-13	Celgene Corporation	Immunological uses of immunomodulatory compounds for vaccines and anti-infectious disease therapy
ZA200901950B (en) *	2006-09-26	2010-06-30	Celgene Corp	5-substituted quinazolinone derivatives as antitumor agents

2008
- 2008-09-25 BR BRPI0817525-0A2A patent/BRPI0817525A2/en not_active Application Discontinuation
- 2008-09-25 SG SG2011080553A patent/SG176442A1/en unknown
- 2008-09-25 WO PCT/US2008/011124 patent/WO2009042177A1/en active Application Filing
- 2008-09-25 EP EP08834539.2A patent/EP2200999B1/en active Active
- 2008-09-25 CA CA2704710A patent/CA2704710C/en not_active Expired - Fee Related
- 2008-09-25 CN CN201410362879.4A patent/CN104211684A/en active Pending
- 2008-09-25 JP JP2010526944A patent/JP5637852B2/en active Active
- 2008-09-25 SG SG10201503486XA patent/SG10201503486XA/en unknown
- 2008-09-25 KR KR1020107008968A patent/KR101593242B1/en not_active Expired - Fee Related
- 2008-09-25 MX MX2010003355A patent/MX347987B/en active IP Right Grant
- 2008-09-25 RU RU2010116273/04A patent/RU2476432C2/en not_active IP Right Cessation
- 2008-09-25 CN CN200880117819.9A patent/CN101952272B/en not_active Expired - Fee Related
- 2008-09-25 US US12/238,354 patent/US8492395B2/en active Active
- 2008-09-25 NZ NZ584425A patent/NZ584425A/en not_active IP Right Cessation
- 2008-09-25 AU AU2008305581A patent/AU2008305581C1/en not_active Ceased
- 2008-09-25 ES ES08834539.2T patent/ES2523925T3/en active Active
- 2008-09-25 MY MYPI2010001343A patent/MY157495A/en unknown
- 2008-09-25 UA UAA201004853A patent/UA102078C2/en unknown
2010
- 2010-03-25 IL IL204763A patent/IL204763A/en active IP Right Grant
- 2010-03-25 NI NI201000041A patent/NI201000041A/en unknown
- 2010-03-31 ZA ZA2010/02303A patent/ZA201002303B/en unknown
- 2010-04-07 CR CR11355A patent/CR11355A/en unknown
- 2010-04-20 CO CO10046034A patent/CO6270228A2/en not_active Application Discontinuation
- 2010-07-05 HK HK10106484.8A patent/HK1139934A1/en not_active IP Right Cessation
2013
- 2013-06-11 IL IL226870A patent/IL226870A/en active IP Right Grant
- 2013-06-26 US US13/928,147 patent/US9096573B2/en active Active
2015
- 2015-06-24 US US14/749,448 patent/US9586929B2/en active Active
2017
- 2017-01-25 US US15/415,332 patent/US9834538B2/en active Active
- 2017-11-07 US US15/806,254 patent/US20180118713A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CR11355A (en)	2010-06-21
ZA201002303B (en)	2011-06-29
EP2200999A1 (en)	2010-06-30
US9586929B2 (en)	2017-03-07
MX347987B (en)	2017-05-22
US20150291555A1 (en)	2015-10-15
SG176442A1 (en)	2011-12-29
US20090093504A1 (en)	2009-04-09
JP5637852B2 (en)	2014-12-10
WO2009042177A1 (en)	2009-04-02
IL226870A0 (en)	2013-07-31
US9096573B2 (en)	2015-08-04
AU2008305581C1 (en)	2014-12-11
ES2523925T3 (en)	2014-12-02
IL204763A0 (en)	2010-11-30
US20180118713A1 (en)	2018-05-03
US8492395B2 (en)	2013-07-23
MX2010003355A (en)	2010-04-14
UA102078C2 (en)	2013-06-10
JP2010540525A (en)	2010-12-24
RU2476432C2 (en)	2013-02-27
US20170129873A1 (en)	2017-05-11
CN101952272A (en)	2011-01-19
EP2200999B1 (en)	2014-08-13
CA2704710A1 (en)	2009-04-02
CA2704710C (en)	2016-02-02
RU2010116273A (en)	2011-11-10
CN104211684A (en)	2014-12-17
KR20100080540A (en)	2010-07-08
SG10201503486XA (en)	2015-06-29
IL226870A (en)	2014-11-30
KR101593242B1 (en)	2016-02-11
US20130289274A1 (en)	2013-10-31
US9834538B2 (en)	2017-12-05
AU2008305581A1 (en)	2009-04-02
NI201000041A (en)	2010-09-09
AU2008305581B2 (en)	2013-12-05
IL204763A (en)	2013-07-31
MY157495A (en)	2016-06-15
CO6270228A2 (en)	2011-04-20
NZ584425A (en)	2012-03-30
CN101952272B (en)	2014-08-27
HK1139934A1 (en)	2010-09-30

Publication	Publication Date	Title
BRPI0817525A2 (en)	2014-11-18	COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATMENT, CONTROL OR PREVENTION OF A DISEASE OR DISORDER.
BR112012004333A2 (en)	2015-09-08	compound, pharmaceutical composition, and method for treating or preventing a disease or disorder.
BRPI0915267A2 (en)	2015-08-18	Compound, pyrogen-free pharmaceutical composition, and method of treating a disease or condition
BRPI0912111A2 (en)	2015-10-06	compound, pharmaceutical composition, method for treating, controlling or preventing a disease or disorder, and, single unit dosage form
BRPI0915382A2 (en)	2017-06-27	compound, pharmaceutical composition, and method for treating a disease or disorder.
BRPI0909768A2 (en)	2015-10-06	compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by activation of b3-adrenoceptor, and use of a compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by b3-adrenoceptor. b3-adrenoceptor activation, and use of a compound
BRPI0815708A2 (en)	2014-09-30	COMPOUND, PRODUCT ESTER, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATING A DISEASE OR CONDITION.
BR112012003464A2 (en)	2015-09-08	compound, pharmaceutical composition, uses of a pharmaceutical composition and a compound, and method for treating a disease or disorder. "
BRPI0717753A2 (en)	2013-10-22	METHOD OF TREATING OR REDUCING THE RISK OF A DISEASE CAUSED BY PROTOZOAN AND, COMPOSITION.
BRPI0815591A2 (en)	2015-03-03	COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE.
BRPI0807046A2 (en)	2015-05-26	Compound, pharmaceutical composition, methods of treating a disorder, cardiovascular disease and a patient suffering from reduced or dysfunctional gastrointestinal motility and, kit.
BRPI1013984A2 (en)	2018-06-19	compound, pharmaceutical composition, method for treating or prophylaxis of a disease or condition, and use of a compound.
BRPI0807749A2 (en)	2014-06-17	COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD FOR THE PREVENTION, TREATMENT OR IMPROVEMENT OF DISEASE DISEASES OR CONDITIONS, OR ACUTE OR CHRONIC CUTANEAL DISORDER DISORDERS.
BRPI0610514A2 (en)	2016-11-16	compound, pharmaceutical composition, and method of treating a disorder
BRPI0716092A2 (en)	2013-09-17	compound or a salt, solvate, or stereoisomer thereof, pharmaceutical composition, method for treating, controlling or preventing a disease or disorder, and, single unit dosage form.
BR112014004181A2 (en)	2017-06-13	compound, pharmaceutical composition, and method of treating, preventing, and / or delaying the onset of a disease or condition
BRPI0820568A2 (en)	2015-06-16	Compound, pharmaceutical composition, use of a compound or pharmaceutical composition, and method of treating a human or animal
BRPI0715845A2 (en)	2014-11-11	PHARMACEUTICAL COMPOSITION FOR LUNG CANCER TREATMENT, GROWTH INHIBITION METHOD OR LUNG CANCER INVASION METHOD
BRPI0819799A2 (en)	2015-05-26	Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease
BRPI1013559A2 (en)	2016-04-12	compounds, pharmaceutical composition, method of treating disease or condition associated with trpa1 function and their uses
BRPI0909179A2 (en)	2015-08-25	Pharmaceutical composition and method of treatment of an autoimmune disease.
BRPI0813001A2 (en)	2019-09-24	neuropathic pain compound, method of treatment or prophylaxis and pharmaceutical composition
BRPI0905758A2 (en)	2015-07-14	Compound, plant disease control method and fungicidal composition
BRPI0909985A2 (en)	2015-08-25	Pharmaceutical composition and method for the treatment or prophylaxis of a viral infection or associated disease
BRPI1013705A2 (en)	2016-04-05	compounds, pharmaceutical composition, method of treating disease or condition associated with trap1 function and uses of compounds and pharmaceutical composition

Legal Events

Date	Code	Title	Description
2015-01-20	B65X	Notification of requirement for priority examination of patent application
2015-03-24	B65Y	Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
2015-04-14	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2015-09-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2016-08-30	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2017-03-21	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2017-07-25	B09B	Patent application refused [chapter 9.2 patent gazette]
2017-10-17	B09B	Patent application refused [chapter 9.2 patent gazette]